Is Asymchem profitable in 2026?

Yes. FY2025 net profit reached RMB 1.13 billion, up 19.35% year over year, on revenue of RMB 6.67 billion (up 14.91%). Q1 2026 revenue grew 16.91% YoY to RMB 1.80 billion, though net profit dipped due to forex losses, as of March 2026.

Who owns Asymchem Laboratories?

Asymchem is publicly traded, dual-listed on Shenzhen Stock Exchange (002821) and Hong Kong Stock Exchange (6821). Its largest shareholder is Asymchem Laboratories, Incorporated, holding about 31.9% of shares as of a 2025 filing, linked to founder and CEO Dr. Hao Hong.

Could AI replace Asymchem's manufacturing business?

Unlikely for its core business. Physical cGMP manufacturing and facility-specific regulatory approvals tied to filed drug programs are largely untouched by AI, as of 2026. Only early-stage route-scouting and screening face AI pressure; Asymchem itself launched an in-house AI platform called AccPCC in July 2026.

Is WuXi AppTec Asymchem's biggest competitor?

WuXi AppTec is the primary Chinese CDMO named as a target under the BIOSECURE Act, signed into US law December 18, 2025. Asymchem is not currently designated, which may let it absorb some diverted Western demand, though Samsung Biologics and CordenPharma are also actively capturing share.

How is Asymchem's peptide and GLP-1 business growing?

In April 2026 Asymchem unveiled an integrated TIDES commercial supply matrix, expanding solid-phase peptide synthesis reactor capacity past 45,000L with a target of about 69,000L by end of 2026, aiming for over 22.5 metric tons of annual peptide output.

How many people work at Asymchem?

Employee counts vary by source: WSJ reported about 9,595 employees as of late December 2025, while Stockanalysis.com and Pitchbook reported 10,617 employees as of mid-2026, suggesting roughly 1,000 net hires tied to capacity expansion.

Biotech tools companies · China

Asymchem Laboratories

asymchem.com ↗

Chinese CDMO making APIs and drug ingredients for global pharma sponsors.

Losing its protection

Assessed 30 July 2026 · Evidence as of 30 July 2026

The structural protection is eroding.

On the recordSince 30 July 2026 · Checkable from December 2026 · Every call on the record Checkpoint: BIOSECURE Act formal designation list release

The call

Asymchem is growing and profitable today, with its main risk sitting outside its own operations, in a US designation list not yet written.

Asymchem makes pharmaceutical ingredients and finished drugs for major Western companies under strict regulatory contracts. It is hard to replace for customers already locked in by years of approval paperwork, but new Western customers are choosing competitors in South Korea, Germany, and the United States instead, spooked by new US laws that could restrict business with Chinese firms. The real test arrives in late 2026 when the US government names which Chinese companies face the toughest restrictions, and whether Asymchem can still land any major new contracts from Western drug makers.

Why

AI pressure: None apparent. AsymBio's own AI hub speeds internal biologics R&D; no AI product is displacing its manufacturing work yet. Could AI do the core job? Unlikely.

Bigger players: Samsung Biologics, CordenPharma, and US reshored CDMO capacity, aided by the BIOSECURE Act. BIOSECURE Act signed Dec 2025 pushes Western sponsors toward non-China CDMOs; Asymchem isn't yet named on any designation list. Could a giant copy it? Probably.

What protects it. Existing cGMP facilities tied into approved NDA/BLA filings are costly for sponsors to swap out mid-program.

What would change this call

BIOSECURE Act designation list (due December 2026) names or broadens scope to include Asymchem. Would confirm Western sponsors are legally forced to exit Asymchem contracts.
Asymchem discloses new Western MSA wins in TIDES/peptides segment through 2027. Would show it can still win new non-Chinese customers despite decoupling pressure.
CordenPharma or Samsung Biologics announce major new GLP-1/peptide capacity or contracts through 2026. Would show rivals actively absorbing demand that might otherwise go to Asymchem.

Key numbers

FY2025 revenue RMB 6.67B, up 14.91% YoY (2025-12-31)
FY2025 net profit RMB 1.13B, up 19.35% YoY (2025-12-31)
SPPS capacity 45,000L now, targeting 69,000L (2026-04-14)

Named risks

BIOSECURE Act formal designation list (due Dec 2026) could add Asymchem or broaden scope. Severity: high
Western sponsor decoupling diverting new CDMO business to Samsung, CordenPharma, US reshored capacity. Severity: high
FX volatility eroded Q1 2026 net profit despite revenue growth. Severity: medium
Rising competitive intensity in peptide/GLP-1 CDMO segment pressuring TIDES pricing. Severity: medium
Inconsistent public data on founding date, capacity figures, and headcount across sources. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
WuXi AppTec	gaining on	WuXi named primary BIOSECURE target (Dec 2025); Asymchem not yet designated, may absorb diverted demand
Samsung Biologics	losing to	Samsung courting clients diversifying from Chinese CDMOs post-BIOSECURE, Oct 2025
CordenPharma	losing to	Acquired AmbioPharm May 2026, directly expanding peptide/GLP-1 CDMO capacity
Novo Nordisk	losing to	Invested $500M in-house Irish GLP-1 capacity, Mar 2026, reducing external CDMO reliance
Lonza	contesting	Global CDMO revenue leader at CHF 8.14B FY2024 vs Asymchem's RMB 6.67B FY2025

Questions people ask

Is Asymchem profitable in 2026?: Yes. FY2025 net profit reached RMB 1.13 billion, up 19.35% year over year, on revenue of RMB 6.67 billion (up 14.91%). Q1 2026 revenue grew 16.91% YoY to RMB 1.80 billion, though net profit dipped due to forex losses, as of March 2026.
Who owns Asymchem Laboratories?: Asymchem is publicly traded, dual-listed on Shenzhen Stock Exchange (002821) and Hong Kong Stock Exchange (6821). Its largest shareholder is Asymchem Laboratories, Incorporated, holding about 31.9% of shares as of a 2025 filing, linked to founder and CEO Dr. Hao Hong.
Could AI replace Asymchem's manufacturing business?: Unlikely for its core business. Physical cGMP manufacturing and facility-specific regulatory approvals tied to filed drug programs are largely untouched by AI, as of 2026. Only early-stage route-scouting and screening face AI pressure; Asymchem itself launched an in-house AI platform called AccPCC in July 2026.
Is WuXi AppTec Asymchem's biggest competitor?: WuXi AppTec is the primary Chinese CDMO named as a target under the BIOSECURE Act, signed into US law December 18, 2025. Asymchem is not currently designated, which may let it absorb some diverted Western demand, though Samsung Biologics and CordenPharma are also actively capturing share.
How is Asymchem's peptide and GLP-1 business growing?: In April 2026 Asymchem unveiled an integrated TIDES commercial supply matrix, expanding solid-phase peptide synthesis reactor capacity past 45,000L with a target of about 69,000L by end of 2026, aiming for over 22.5 metric tons of annual peptide output.
How many people work at Asymchem?: Employee counts vary by source: WSJ reported about 9,595 employees as of late December 2025, while Stockanalysis.com and Pitchbook reported 10,617 employees as of mid-2026, suggesting roughly 1,000 net hires tied to capacity expansion.

Timeline

2026-07-27AsymBio breaks ground on 20,000 sq-m Shanghai Fengxian R&D building, commissioning H2 2027
2026-05-27CordenPharma acquires AmbioPharm, expanding peptide/GLP-1 CDMO capacity
2026-04-14Asymchem unveils TIDES commercial supply matrix, SPPS capacity over 45,000L
2026-03-31Q1 2026 revenue RMB 1.80B, up 16.91% YoY; net profit falls on forex losses
2026-03-01Novo Nordisk invests $500M in Irish facility for in-house oral GLP-1 manufacturing
2025-12-31FY2025 results: revenue RMB 6.67B (+14.91%), net profit RMB 1.13B (+19.35%)
2025-12-18BIOSECURE Act signed into US law, naming WuXi as primary target
2025-10-30Samsung Biologics reported courting clients diversifying from Chinese CDMOs
2024-12-31FY2024 revenue falls to RMB 5.80B from RMB 7.78B in FY2023

Revision history

30 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation